[
  {
    "ts": null,
    "headline": "Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board",
    "summary": "WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. D",
    "url": "https://finnhub.io/api/news?id=a02eecee70fee08f718d3f98895953f8f7887435ae39693351055689beace273",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771880460,
      "headline": "Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board",
      "id": 139188150,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. D",
      "url": "https://finnhub.io/api/news?id=a02eecee70fee08f718d3f98895953f8f7887435ae39693351055689beace273"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear",
    "summary": "Moderna made a fortune with COVID vaccines, but revenue has since declined.",
    "url": "https://finnhub.io/api/news?id=5c8077ec13bcdd499f7a5b26b12376d3cc71dad54af574388410a06b23540b73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771856400,
      "headline": "Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear",
      "id": 139185070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna made a fortune with COVID vaccines, but revenue has since declined.",
      "url": "https://finnhub.io/api/news?id=5c8077ec13bcdd499f7a5b26b12376d3cc71dad54af574388410a06b23540b73"
    }
  },
  {
    "ts": null,
    "headline": "Update: BioNTech Sues Moderna Over COVID-19 Vaccine Technology Patent",
    "summary": "(Updates with Moderna's response in the fifth paragraph.) BioNTech (BNTX) sued rival Moderna (MRN",
    "url": "https://finnhub.io/api/news?id=3ed841e72c7c81d3dfea3fdae055c6ddd0e4ac7f4bd6cd294582bab4369bbb2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771844482,
      "headline": "Update: BioNTech Sues Moderna Over COVID-19 Vaccine Technology Patent",
      "id": 139183162,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "(Updates with Moderna's response in the fifth paragraph.) BioNTech (BNTX) sued rival Moderna (MRN",
      "url": "https://finnhub.io/api/news?id=3ed841e72c7c81d3dfea3fdae055c6ddd0e4ac7f4bd6cd294582bab4369bbb2a"
    }
  }
]